

KYT OPEN

Healthy and functional cells from discovery to manufacturing

June 2021

hello@kytopen.com

IMPACT

PASSION

INTEGRITY

RESILIENCE

INCLUSIVITY


Promise...and Challenges of Cell Therapies

KYTO[®]PEN

Today's Approved Therapies

Autologous
Viral
Single gene modification
Small payloads
Expensive (\$0.5M-\$2M)
Variable MFG

Example of Cell Therapy Manufacturing



Tomorrow's Approved Therapies

Autologous & Allogeneic
Viral & Non-Viral
Multiple gene edits
Large payloads
Cost-effective
Consistent MFG

Kytopen Enables Next-Gen Cell Therapies


KYTOPEN

**Kytopen delivers therapeutic solutions to the clinic faster,
for the benefit of mankind.**

“It’s the same.”

Flowfect® Array

R&D
(~100 µL)



Flowfect® Tx




Manufacturing
(>10 mL)

Fully automated process

Factor
100x - 1,000x

Throughput > 1 billion cells/min

Flowfect[®] equivalent at small and large scale

KYTO[®]PEN

Flowfect[®] Array platform optimization parameters scale to the *Flowfect*[®] Tx platform with no difference observed in cell viability or delivery efficiency between the platforms (functionally equivalent <5% difference)

Kytopen *Flowfect*® Delivery Progress

KYTOPEN



Kytopen Management Team

KYTOPEN



Paulo Garcia, Ph.D.
CEO & Co-Founder
Corporate Strategy,
BD & Partnerships,
Biomedical Engineer




Cullen Buie, Ph.D.
CTO & Co-Founder
MIT Faculty (MechE),
Tech. Development, IP,
Collaborations



Bethany Grant
Head of R&D
Aero/Mech Eng
Med Device Development
J&J, Atlantis (AZ acquired)



Michael Elliott
COO
Global Operations
P&L Management
MBA/Mech Eng



Greg Crescenzi
Chief Commercial Officer
Innovative Technologies
Prior: Cytiva/GE Healthcare,
BD, Pall, & Merck Millipore



Theresa Tribble
Board Member
Operating Partner, The Engine
Prior: EverlyWell (CBO),
SynapDx (VP Commercial)

Kytopen (MIT spinout)

Financing

- \$9M in funds raised to date (dilutive + non-dilutive) secured
- \$2M NIH (NK cells) SBIR (Priority Score: 27) **Intent to Award**

Intellectual Property

- 5 patents for *Flowfect*® apparatus, kits, and methods of use
- Exclusive license for MIT portfolio (2 patents USA & EU)
- Kytopen wholly-owned portfolio (3 pending-patents WW)

Investors

- The Engine
- Horizons Ventures
- MassVentures
- Experienced Biotech Angels



Breakthrough Bioinnovation
Flowfect™ Tx Co-Development



Cell & Gene Therapy Experts
Regulatory Strategy

KYT OPEN

Healthy and functional cells from discovery to manufacturing

June 2021

hello@kytopen.com

IMPACT

PASSION

INTEGRITY

RESILIENCE

INCLUSIVITY